Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable >= Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey
Tarih
2019Yazar
Beksac, Meral
Seval, Guldane Cengiz
Paydas, Semra
Tuglular, Tulin Firatli
Arslan, Onder
Goker, Hakan
Kaynar, Leylagul
Altuntas, Fevzi
Atalay, Figen
Teke, Havva Uskudar
Bolaman, Ali Zahit
Pehlivan, Mustafa
Sonmez, Mehmet
Demir, Ahmet Muzaffer
Topcuoglu, Pervin
Yilmaz, Mehmet
Kabukcu, Sibel Hacioglu
Albayrak, Murat
Yurttas, Nurgul Ozer
Salihoglu, Ayse
Cakar, Merih Kizil
Gurman, Gunhan